Table 2.
Clinical Response to Nivolumab
| Response | Total (n = 17) |
|
|---|---|---|
| n | % (95% CI) | |
| ORR | 5 | 29.4 (10.3–56.0) |
| Complete response | 0 | 0 |
| Partial response | 5 | 29.4 |
| Stable disease | 5 | 29.4 |
| Controlled disease | 10 | 58.8 (32.9–81.6) |
| Progressive disease | 5 | 29.4 |
| Not assessable | 2 | 11.8 |
| Duration of response (mo), median | 6.5 | (3.68–8.84) |
CI, confidence interval; ORR, objective response rate.